ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.848,77
-0,34%
S&P 500
6.040,04
1,10%
Dow Jones
43.297,03
0,91%
Euro vs US Dollar
1,04255
0,21%
Bitcoin
98.403,83
-0,28%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Biogen Inc (BIIB)

  7. Biogen Inc (BIIB) News

BIIB

Biogen (BIIB)

Biogen Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BIIB
DatumZeitQuelleÜberschriftSymbolFirma
09/12/202422h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
09/12/202422h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
09/12/202416h33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BIIBBiogen Inc
05/12/202400h31PR Newswire (US)"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in MexicoNASDAQ:BIIBBiogen Inc
28/11/202401h31PR Newswire (US)"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South KoreaNASDAQ:BIIBBiogen Inc
19/11/202407h00GlobeNewswire Inc.Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease ActivityNASDAQ:BIIBBiogen Inc
14/11/202419h29PR Newswire (US)Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's DiseaseNASDAQ:BIIBBiogen Inc
14/11/202417h23GlobeNewswire Inc.Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s DiseaseNASDAQ:BIIBBiogen Inc
07/11/202422h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
04/11/202422h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
31/10/202400h30GlobeNewswire Inc.Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) ConferenceNASDAQ:BIIBBiogen Inc
30/10/202421h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIIBBiogen Inc
30/10/202421h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BIIBBiogen Inc
30/10/202411h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIIBBiogen Inc
30/10/202411h37IH Market NewsUS Futures Rise as Tech Earnings Drive Market Optimism; Oil Prices Edge UpNASDAQ:BIIBBiogen Inc
29/10/202423h00GlobeNewswire Inc.Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological DiseasesNASDAQ:BIIBBiogen Inc
29/10/202413h00GlobeNewswire Inc.Biogen Appoints Daniel Quirk, MD, as Chief Medical OfficerNASDAQ:BIIBBiogen Inc
28/10/202413h30GlobeNewswire Inc.Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025NASDAQ:BIIBBiogen Inc
27/10/202402h15GlobeNewswire Inc.Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024NASDAQ:BIIBBiogen Inc
24/10/202413h30GlobeNewswire Inc.Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual ConferenceNASDAQ:BIIBBiogen Inc
22/10/202413h30GlobeNewswire Inc.Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024NASDAQ:BIIBBiogen Inc
09/10/202413h30GlobeNewswire Inc.Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant RecipientsNASDAQ:BIIBBiogen Inc
08/10/202413h30GlobeNewswire Inc.New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMANASDAQ:BIIBBiogen Inc
08/10/202401h08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
24/09/202407h00GlobeNewswire Inc.UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024NASDAQ:BIIBBiogen Inc
12/09/202413h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIIBBiogen Inc
12/09/202413h30GlobeNewswire Inc.Biogen Board Appoints Two New Independent DirectorsNASDAQ:BIIBBiogen Inc
05/09/202412h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
04/09/202413h30GlobeNewswire Inc.Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMANASDAQ:BIIBBiogen Inc
03/09/202419h00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BIIBBiogen Inc
 Showing the most relevant articles for your search:NASDAQ:BIIB

Kürzlich von Ihnen besucht

COIN
AVAXUSD
Avalanche
USOTC
BASFY
BASF (QX)
TG
D7G
Nel ASA
TG
432
Arbor Metals
NYSE
DIS
Walt Disney
TG
DBK
Deutsche Bank
NYSE
XOM
Exxon Mobil
AMEX
XLV
Health Care Select Sector
NASDAQ
MSFT
Microsoft
TG
NOV
Novo Nordisk
USOTC
BNPQY
BNP Paribas (QX)
AMEX
SPY
SPDR S&P 500
NYSE
NKE
Nike
USOTC
RHHBY
Roche (QX)
CCOM
US30
US 30
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten